Involvement of interleukin-6-regulated nitric oxide synthase in hemorrhagic cystitis and impaired bladder contractions in young rats induced by acrolein, a urinary metabolite of cyclophosphamide

Toxicological Sciences

Volumn 131, Issue 1, 2013, Pages 302-310

  Wang, Ching Chia ^a   Weng, Te I ^b   Wu, En Ting ^a   Wu, Mei Hwan ^a   Yang, Rong Sen ^a   Liu, Shing Hwa ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Acrolein; Bladder contraction; Cyclophosphamide; Hemorrhagic cystitis

Indexed keywords

3 [8 [(DIMETHYLAMINO)METHYL] 6,7,8,9 TETRAHYDROPYRIDO[1,2 A]INDOL 10 YL] 4 (1 METHYL 1H INDOL 3 YL) 1H PYRROLE 2,5 DIONE; ACROLEIN; CYCLOPHOSPHAMIDE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; NEUTRALIZING ANTIBODY; NITRIC OXIDE SYNTHASE; PROTEIN KINASE C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CONTRACTION DISORDER; BLADDER DYSFUNCTION; CONTROLLED STUDY; FEMALE; HEMORRHAGIC CYSTITIS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT;

ACROLEIN; ANIMALS; BLOTTING, WESTERN; CYCLOPHOSPHAMIDE; CYSTITIS; FEMALE; HEMORRHAGE; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; MUSCLE CONTRACTION; MUSCLE, SMOOTH; NITRIC OXIDE SYNTHASE TYPE II; RATS; RATS, WISTAR; URINARY BLADDER;

RATTUS;

EID: 84872403347     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfs270     Document Type: Article

References (37)

1. Abraham, P., Rabi, S., and Kulothungan, P. (2009). Aminoguanidine, selective nitric oxide synthase inhibitor, ameliorates cyclophosphamide-induced hemorrhagic cystitis by inhibiting protein nitration and PARS activation. Urology 73, 1402-1406
2. Al-Rawithi, S., El-Yazigi, A., Ernst, P., Al-Fiar, F., and Nicholls, P. J. (1998). Urinary excretion and pharmacokinetics of acrolein and its parent drug cyclophosphamide in bone marrow transplant patients. Bone Marrow Transplant. 22, 485-490.
3. Andrews, B., Shariat, S. F., Kim, J. H., Wheeler, T. M., Slawin, K. M., and Lerner, S. P. (2002). Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer. J. Urol. 167, 1475-1481.
4. Batista, C. K., Brito, G. A., Souza, M. L., Leitão, B. T., Cunha, F. Q., and Ribeiro, R. A. (2006). A model of hemorrhagic cystitis induced with acrolein in mice. Braz. J. Med. Biol. Res. 39, 1475-1481.
5. Batista, C. K., Mota, J. M., Souza, M. L., Leitão, B. T., Souza, M. H., Brito, G. A., Cunha, F. Q., and Ribeiro, R. A. (2007). Amifostine and glutathione prevent ifosfamide- and acrolein-induced hemorrhagic cystitis. Cancer Chemother. Pharmacol. 59, 71-77.
6. Bouchelouche, K., Alvarez, S., Horn, T., Nordling, J., and Bouchelouche, P. (2006). Human detrusor smooth muscle cells release interleukin-6, interleukin-8, and RANTES in response to proinflammatory cytokines interleukin-1beta and tumor necrosis factor-α. Urology 67, 214-219.
7. Brock, N., and Pohl, J. (1983). The development of mesna for regional detoxification. Cancer Treat. Rev. 10(SUPPL. A), 33-43.
8. Brock, N., Pohl, J., and Stekar, J. (1981). Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention. 2. Comparative study on the uroprotective efficacy of thiols and other sulfur compounds. Eur. J. Cancer Clin. Oncol. 17, 1155-1163.
9. Carli, M., Passone, E., Perilongo, G., and Bisogno, G. (2003). Ifosfamide in pediatric solid tumors. Oncology 65(SUPPL. 2), 99-104.
10. de Jonge, M. E., Huitema, A. D., Rodenhuis, S., and Beijnen, J. H. (2005). Clinical pharmacokinetics of cyclophosphamide. Clin. Pharmacokinet. 44, 1135-1164.
11. Dechant, K. L., Brogden, R. N., Pilkington, T., and Faulds, D. (1991). Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer. Drugs 42, 428-467.
12. el-Yazigi, A., Ernst, P., al-Rawithi, S., Legayada, E., and Raines, D. A. (1997). Pharmacokinetics of mesna and dimesna after simultaneous intravenous bolus and infusion administration in patients undergoing bone marrow transplantation. J. Clin. Pharmacol. 37, 618-624.
13. Fraiser, L., and Kehrer, J. P. (1992). Murine strain differences in metabolism and bladder toxicity of cyclophosphamide. Toxicology 75, 257-272.
14. Gomes, T. N., Santos, C. C., Souza-Filho, M. V., Cunha, F. Q., and Ribeiro, R. A. (1995). Participation of TNF-alpha and IL-1 in the pathogenesis of cyclophosphamide-induced hemorrhagic cystitis. Braz. J. Med. Biol. Res. 28, 1103-1108.
15. Gray, K. J., Engelmann, U. H., Johnson, E. H., and Fishman, I. J. (1986). Evaluation of misoprostol cytoprotection of the bladder with cyclophosphamide (Cytoxan) therapy. J. Urol. 136, 497-500.
16. Hassan, Z. (2011). Management of refractory hemorrhagic cystitis following hematopoietic stem cell transplantation in children. Pediatr. Transplant. 15, 348-361.
17. James, M. J., Birmingham, A. T., and Hill, S. J. (1993). Partial mediation by nitric oxide of the relaxation of human isolated detrusor strips in response to electrical field stimulation. Br. J. Clin. Pharmacol. 35, 366-372.
18. Kiuchi, H., Takao, T., Yamamoto, K., Nakayama, J., Miyagawa, Y., Tsujimura, A., Nonomura, N., and Okuyama, A. (2009). Sesquiterpene lactone parthenolide ameliorates bladder inflammation and bladder overactivity in cyclophosphamide induced rat cystitis model by inhibiting nuclear factor-kappaB phosphorylation. J. Urol. 181, 2339-2348.
19. Korkmaz, A., Topal, T., and Oter, S. (2007). Pathophysiological aspects of cyclophosphamide and ifosfamide induced hemorrhagic cystitis; implication of reactive oxygen and nitrogen species as well as PARP activation. Cell Biol. Toxicol. 23, 303-312.
20. Levine, L. A., and Richie, J. P. (1989). Urological complications of cyclophosphamide. J. Urol. 141, 1063-1069.
21. Liu, S. H., and Lin-Shiau, S. Y. (2000). Protein kinase c regulates purinergic component of neurogenic contractions in mouse bladder. J. Urol. 164, 1764-1767.
22. Macedo, F. Y., Baltazar, F., Almeida, P. R., Távora, F., Ferreira, F. V., Schmitt, F. C., Brito, G. A., and Ribeiro, R. A. (2008). Cyclooxygenase-2 expression on ifosfamide-induced hemorrhagic cystitis in rats. J. Cancer Res. Clin. Oncol. 134, 19-27.
23. Mamas, M. A., Reynard, J. M., and Brading, A. F. (2003). Nitric oxide and the lower urinary tract: Current concepts, future prospects. Urology 61, 1079-1085.
24. Neuhaus, J., Schlichting, N., Oberbach, A., and Stolzenburg, J. U. (2007). [Lipopolysaccharide-mediated regulation of interleukin-6 in cultured human detrusor smooth muscle cells]. Urologe. A 46, 1193-1197.
25. Nishii, H., Nomura, M., Fujimoto, N., and Matsumoto, T. (2006). Up-regulation of interleukin-6 gene expression in cyclophosphamide-induced cystitis in mice: An in situ hybridization histochemical study. Int. J. Urol. 13, 1339-1343.
26. Oter, S., Korkmaz, A., Oztas, E., Yildirim, I., Topal, T., and Bilgic, H. (2004). Inducible nitric oxide synthase inhibition in cyclophosphamide induced hemorrhagic cystitis in rats. Urol. Res. 32, 185-189.
27. Philips, F. S., Sternberg, S. S., Cronin, A. P., and Vidal, P. M. (1961). Cyclophosphamide and urinary bladder toxicity. Cancer Res. 21, 1577-1589.
28. Ribeiro, R. A., Freitas, H. C., Campos, M. C., Santos, C. C., Figueiredo, F. C., Brito, G. A., and Cunha, F. Q. (2002). Tumor necrosis factor-alpha and interleukin-1beta mediate the production of nitric oxide involved in the pathogenesis of ifosfamide induced hemorrhagic cystitis in mice. J. Urol. 167, 2229-2234.
29. Sencer, S. F., Haake, R. J., and Weisdorf, D. J. (1993). Hemorrhagic cystitis after bone marrow transplantation. Risk factors and complications. Transplantation 56, 875-879.
30. Taga, T., and Kishimoto, T. (1997). Gp130 and the interleukin-6 family of cytokines. Annu. Rev. Immunol. 15, 797-819.
31. Tasso, M. J., Boddy, A. V., Price, L., Wyllie, R. A., Pearson, A. D., and Idle, J. R. (1992). Pharmacokinetics and metabolism of cyclophosphamide in paediatric patients. Cancer Chemother. Pharmacol. 30, 207-211.
32. Virág, L., and Szabó, C. (2002). The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol. Rev. 54, 375-429.
33. Walterhouse, D., and Watson, A. (2007). Optimal management strategies for rhabdomyosarcoma in children. Paediatr. Drugs 9, 391-400.
34. Watson, N. A., and Notley, R. G. (1973). Urological complications of cyclophosphamide. Br. J. Urol. 45, 606-609.
35. Weng, T. I., Chen, W. J., and Liu, S. H. (2005). Bladder instillation of Escherichia coli lipopolysaccharide alters the muscle contractions in rat urinary bladder via a protein kinase C-related pathway. Toxicol. Appl. Pharmacol. 208, 163-169.
36. Weng, T. I., Chen, W. J., Wu, H. Y., and Liu, S. H. (2006). Uropathogenic Escherichia coli alters muscle contractions in rat urinary bladder via a nitric oxide synthase-related signaling pathway. J. Infect. Dis. 194, 1774-1782.
37. Weng, T. I., Wu, H. Y., Lin, P. Y., and Liu, S. H. (2009). Uropathogenic Escherichia coli-induced inflammation alters mouse urinary bladder contraction via an interleukin-6-activated inducible nitric oxide synthase-related pathway. Infect. Immun. 77, 3312-3319.